U.S. pharma large copyright scrapped two experimental weight loss drugs previous yr—a at the time-day-to-day capsule, lotiglipron, on account of elevated liver enzymes in addition to a twice-every day tablet, danuglipron, because of powerful side effects—but CEO Albert Bourla has claimed the company is determined to “Participate in and get”